• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of biochemjBJ Latest papers and much more!
Biochem J. Dec 15, 2000; 352(Pt 3): 601–610.
PMCID: PMC1221494

The latent transforming growth factor beta binding protein (LTBP) family.


The transforming growth factor beta (TGFbeta) cytokines are a multi-functional family that exert a wide variety of effects on both normal and transformed mammalian cells. The secretion and activation of TGFbetas is regulated by their association with latency-associated proteins and latent TGFbeta binding proteins (LTBPs). Over the past few years, three members of the LTBP family have been identified, in addition to the protoype LTBP1 first sequenced in 1990. Three of the LTBP family are expressed in a variety of isoforms as a consequence of alternative splicing. This review summarizes the differences between the isoforms in terms of the effects on domain structure and hence possible function. The close identity between LTBPs and members of the fibrillin family, mutations in which have been linked directly to Marfan's syndrome, suggests that anomalous expression of LTBPs may be associated with disease. Recent data indicating that differential expression of LTBP1 isoforms occurs during the development of coronary heart disease is considered, together with evidence that modulation of LTBP function, and hence of TGFbeta activity, is associated with a variety of cancers.

Full Text

The Full Text of this article is available as a PDF (218K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engström U, Heldin CH. Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem. 1992 Sep 25;267(27):19482–19488. [PubMed]
  • Miyazono K, Hellman U, Wernstedt C, Heldin CH. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem. 1988 May 5;263(13):6407–6415. [PubMed]
  • Wakefield LM, Smith DM, Flanders KC, Sporn MB. Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. J Biol Chem. 1988 Jun 5;263(16):7646–7654. [PubMed]
  • Kanzaki T, Olofsson A, Morén A, Wernstedt C, Hellman U, Miyazono K, Claesson-Welsh L, Heldin CH. TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences. Cell. 1990 Jun 15;61(6):1051–1061. [PubMed]
  • Okada F, Yamaguchi K, Ichihara A, Nakamura T. Purification and structural analysis of a latent form of transforming growth factor-beta from rat platelets. J Biochem. 1989 Aug;106(2):304–310. [PubMed]
  • Tsuji T, Okada F, Yamaguchi K, Nakamura T. Molecular cloning of the large subunit of transforming growth factor type beta masking protein and expression of the mRNA in various rat tissues. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8835–8839. [PMC free article] [PubMed]
  • Olofsson A, Ichijo H, Morén A, ten Dijke P, Miyazono K, Heldin CH. Efficient association of an amino-terminally extended form of human latent transforming growth factor-beta binding protein with the extracellular matrix. J Biol Chem. 1995 Dec 29;270(52):31294–31297. [PubMed]
  • Gibson MA, Hatzinikolas G, Davis EC, Baker E, Sutherland GR, Mecham RP. Bovine latent transforming growth factor beta 1-binding protein 2: molecular cloning, identification of tissue isoforms, and immunolocalization to elastin-associated microfibrils. Mol Cell Biol. 1995 Dec;15(12):6932–6942. [PMC free article] [PubMed]
  • Morén A, Olofsson A, Stenman G, Sahlin P, Kanzaki T, Claesson-Welsh L, ten Dijke P, Miyazono K, Heldin CH. Identification and characterization of LTBP-2, a novel latent transforming growth factor-beta-binding protein. J Biol Chem. 1994 Dec 23;269(51):32469–32478. [PubMed]
  • Bashir MM, Han MD, Abrams WR, Tucker T, Ma RI, Gibson M, Ritty T, Mecham R, Rosenbloom J. Analysis of the human gene encoding latent transforming growth factor-beta-binding protein-2. Int J Biochem Cell Biol. 1996 May;28(5):531–542. [PubMed]
  • Fang J, Li X, Smiley E, Francke U, Mecham RP, Bonadio J. Mouse latent TGF-beta binding protein-2: molecular cloning and developmental expression. Biochim Biophys Acta. 1997 Nov 20;1354(3):219–230. [PubMed]
  • Yin W, Smiley E, Germiller J, Mecham RP, Florer JB, Wenstrup RJ, Bonadio J. Isolation of a novel latent transforming growth factor-beta binding protein gene (LTBP-3). J Biol Chem. 1995 Apr 28;270(17):10147–10160. [PubMed]
  • Li X, Yin W, Pérez-Jurado L, Bonadio J, Francke U. Mapping of human and murine genes for latent TGF-beta binding protein-2 (LTBP2). Mamm Genome. 1995 Jan;6(1):42–45. [PubMed]
  • Giltay R, Kostka G, Timpl R. Sequence and expression of a novel member (LTBP-4) of the family of latent transforming growth factor-beta binding proteins. FEBS Lett. 1997 Jul 14;411(2-3):164–168. [PubMed]
  • Massagué J. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990;6:597–641. [PubMed]
  • de Larco JE, Todaro GJ. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci U S A. 1978 Aug;75(8):4001–4005. [PMC free article] [PubMed]
  • Roberts AB, Lamb LC, Newton DL, Sporn MB, De Larco JE, Todaro GJ. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci U S A. 1980 Jun;77(6):3494–3498. [PMC free article] [PubMed]
  • Anzano MA, Roberts AB, Smith JM, Sporn MB, De Larco JE. Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. Proc Natl Acad Sci U S A. 1983 Oct;80(20):6264–6268. [PMC free article] [PubMed]
  • Nishio E, Watanabe Y. Transforming growth factor beta is a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for catalase activity and glutathione peroxidase activity. Biochem Biophys Res Commun. 1997 Mar 6;232(1):1–4. [PubMed]
  • Siese A, Jaros PP, Willig A. Analysis of interleukin (IL)-1 beta and transforming growth factor (TGF)-beta-induced signal transduction pathways in IL-2 and TGF-beta secretion and proliferation in the thymoma cell line EL4.NOB-1. Scand J Immunol. 1999 Feb;49(2):139–148. [PubMed]
  • Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986 Mar 25;261(9):4337–4345. [PubMed]
  • Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167–4171. [PMC free article] [PubMed]
  • Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5788–5792. [PMC free article] [PubMed]
  • Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J. 1987 Jun;6(6):1633–1636. [PMC free article] [PubMed]
  • Gohongi T, Fukumura D, Boucher Y, Yun CO, Soff GA, Compton C, Todoroki T, Jain RK. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta1. Nat Med. 1999 Oct;5(10):1203–1208. [PubMed]
  • Parsons-Wingerter P, Elliott KE, Farr AG, Radhakrishnan K, Clark JI, Sage EH. Generational analysis reveals that TGF-beta1 inhibits the rate of angiogenesis in vivo by selective decrease in the number of new vessels. Microvasc Res. 2000 Mar;59(2):221–232. [PubMed]
  • Bonewald LF, Dallas SL. Role of active and latent transforming growth factor beta in bone formation. J Cell Biochem. 1994 Jul;55(3):350–357. [PubMed]
  • Kimchi A, Wang XF, Weinberg RA, Cheifetz S, Massagué J. Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells. Science. 1988 Apr 8;240(4849):196–199. [PubMed]
  • Inagaki M, Moustakas A, Lin HY, Lodish HF, Carr BI. Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5359–5363. [PMC free article] [PubMed]
  • Damstrup L, Rygaard K, Spang-Thomsen M, Skovgaard Poulsen H. Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2 and TGF beta 3 in human small cell lung cancer cell lines. Br J Cancer. 1993 May;67(5):1015–1021. [PMC free article] [PubMed]
  • Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, Sporn MB. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8772–8776. [PMC free article] [PubMed]
  • Glick AB, Kulkarni AB, Tennenbaum T, Hennings H, Flanders KC, O'Reilly M, Sporn MB, Karlsson S, Yuspa SH. Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6076–6080. [PMC free article] [PubMed]
  • Jirtle RL, Haag JD, Ariazi EA, Gould MN. Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res. 1993 Sep 1;53(17):3849–3852. [PubMed]
  • Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000 May 4;342(18):1350–1358. [PubMed]
  • Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang XF, Brattain MG. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem. 1994 Oct 21;269(42):26449–26455. [PubMed]
  • Villanueva A, García C, Paules AB, Vicente M, Megías M, Reyes G, de Villalonga P, Agell N, Lluís F, Bachs O, et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene. 1998 Oct 15;17(15):1969–1978. [PubMed]
  • Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. 1999 Jan 15;59(2):320–324. [PubMed]
  • Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999 Feb 11;397(6719):530–534. [PubMed]
  • Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 1996 Aug 23;86(4):531–542. [PubMed]
  • Grainger DJ, Metcalfe JC. A pivotal role for TGF-beta in atherogenesis? Biol Rev Camb Philos Soc. 1995 Nov;70(4):571–596. [PubMed]
  • Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994 Aug 11;370(6489):460–462. [PubMed]
  • Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med. 1995 Jan;1(1):74–79. [PubMed]
  • Grainger DJ, Mosedale DE, Metcalfe JC. TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):133–145. [PubMed]
  • Corson GM, Chalberg SC, Dietz HC, Charbonneau NL, Sakai LY. Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end. Genomics. 1993 Aug;17(2):476–484. [PubMed]
  • Koski C, Saharinen J, Keski-Oja J. Independent promoters regulate the expression of two amino terminally distinct forms of latent transforming growth factor-beta binding protein-1 (LTBP-1) in a cell type-specific manner. J Biol Chem. 1999 Nov 12;274(46):32619–32630. [PubMed]
  • Gleizes PE, Beavis RC, Mazzieri R, Shen B, Rifkin DB. Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta1. J Biol Chem. 1996 Nov 22;271(47):29891–29896. [PubMed]
  • Saharinen J, Taipale J, Keski-Oja J. Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J. 1996 Jan 15;15(2):245–253. [PMC free article] [PubMed]
  • Yin W, Fang J, Smiley E, Bonadio J. 8-Cysteine TGF-BP structural motifs are the site of covalent binding between mouse LTBP-3, LTBP-2, and latent TGF-beta 1. Biochim Biophys Acta. 1998 Apr 2;1383(2):340–350. [PubMed]
  • Yuan X, Downing AK, Knott V, Handford PA. Solution structure of the transforming growth factor beta-binding protein-like module, a domain associated with matrix fibrils. EMBO J. 1997 Nov 17;16(22):6659–6666. [PMC free article] [PubMed]
  • Rosenbloom J, Abrams WR, Mecham R. Extracellular matrix 4: the elastic fiber. FASEB J. 1993 Oct;7(13):1208–1218. [PubMed]
  • Sakai LY, Keene DR, Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol. 1986 Dec;103(6 Pt 1):2499–2509. [PMC free article] [PubMed]
  • Zhang H, Apfelroth SD, Hu W, Davis EC, Sanguineti C, Bonadio J, Mecham RP, Ramirez F. Structure and expression of fibrillin-2, a novel microfibrillar component preferentially located in elastic matrices. J Cell Biol. 1994 Mar;124(5):855–863. [PMC free article] [PubMed]
  • Colosetti P, Hellman U, Heldin CH, Miyazono K. Ca2+ binding of latent transforming growth factor-beta 1 binding protein. FEBS Lett. 1993 Apr 5;320(2):140–144. [PubMed]
  • Reinhardt DP, Mechling DE, Boswell BA, Keene DR, Sakai LY, Bächinger HP. Calcium determines the shape of fibrillin. J Biol Chem. 1997 Mar 14;272(11):7368–7373. [PubMed]
  • Reinhardt DP, Ono RN, Notbohm H, Müller PK, Bächinger HP, Sakai LY. Mutations in calcium-binding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis. A potential disease-causing mechanism in Marfan syndrome. J Biol Chem. 2000 Apr 21;275(16):12339–12345. [PubMed]
  • Saharinen J, Taipale J, Monni O, Keski-Oja J. Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4. J Biol Chem. 1998 Jul 17;273(29):18459–18469. [PubMed]
  • Oklü R, Metcalfe JC, Hesketh TR, Kemp PR. Loss of a consensus heparin binding site by alternative splicing of latent transforming growth factor-beta binding protein-1. FEBS Lett. 1998 Mar 27;425(2):281–285. [PubMed]
  • Oklü R, Hesketh TR, Metcalfe JC, Kemp PR. Expression of alternatively spliced human latent transforming growth factor beta binding protein-1. FEBS Lett. 1998 Sep 18;435(2-3):143–148. [PubMed]
  • Gong W, Roth S, Michel K, Gressner AM. Isoforms and splice variant of transforming growth factor beta-binding protein in rat hepatic stellate cells. Gastroenterology. 1998 Feb;114(2):352–363. [PubMed]
  • Yin W, Smiley E, Bonadio J. Alternative splicing of LTBP-3. Biochem Biophys Res Commun. 1998 Apr 17;245(2):454–458. [PubMed]
  • Adès LC, Haan EA, Colley AF, Richard RI. Characterisation of four novel fibrillin-1 (FBN1) mutations in Marfan syndrome. J Med Genet. 1996 Aug;33(8):665–671. [PMC free article] [PubMed]
  • Dietz HC, Valle D, Francomano CA, Kendzior RJ, Jr, Pyeritz RE, Cutting GR. The skipping of constitutive exons in vivo induced by nonsense mutations. Science. 1993 Jan 29;259(5095):680–683. [PubMed]
  • Liu W, Qian C, Francke U. Silent mutation induces exon skipping of fibrillin-1 gene in Marfan syndrome. Nat Genet. 1997 Aug;16(4):328–329. [PubMed]
  • Nunes I, Gleizes PE, Metz CN, Rifkin DB. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol. 1997 Mar 10;136(5):1151–1163. [PMC free article] [PubMed]
  • Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem. 1997 Mar 14;272(11):7151–7158. [PubMed]
  • Rebay I, Fleming RJ, Fehon RG, Cherbas L, Cherbas P, Artavanis-Tsakonas S. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. Cell. 1991 Nov 15;67(4):687–699. [PubMed]
  • Fülöp C, Walcz E, Valyon M, Glant TT. Expression of alternatively spliced epidermal growth factor-like domains in aggrecans of different species. Evidence for a novel module. J Biol Chem. 1993 Aug 15;268(23):17377–17383. [PubMed]
  • Smas CM, Green D, Sul HS. Structural characterization and alternate splicing of the gene encoding the preadipocyte EGF-like protein pref-1. Biochemistry. 1994 Aug 9;33(31):9257–9265. [PubMed]
  • Liu W, Qian C, Comeau K, Brenn T, Furthmayr H, Francke U. Mutant fibrillin-1 monomers lacking EGF-like domains disrupt microfibril assembly and cause severe marfan syndrome. Hum Mol Genet. 1996 Oct;5(10):1581–1587. [PubMed]
  • Miyazono K, Olofsson A, Colosetti P, Heldin CH. A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J. 1991 May;10(5):1091–1101. [PMC free article] [PubMed]
  • Dallas SL, Park-Snyder S, Miyazono K, Twardzik D, Mundy GR, Bonewald LF. Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. J Biol Chem. 1994 Mar 4;269(9):6815–6821. [PubMed]
  • Koli K, Keski-Oja J. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res. 1995 Apr 1;55(7):1540–1546. [PubMed]
  • Miyazono K, Thyberg J, Heldin CH. Retention of the transforming growth factor-beta 1 precursor in the Golgi complex in a latent endoglycosidase H-sensitive form. J Biol Chem. 1992 Mar 15;267(8):5668–5675. [PubMed]
  • Kirschenlohr HL, Metcalfe JC, Weissberg PL, Grainger DJ. Adult human aortic smooth muscle cells in culture produce active TGF-beta. Am J Physiol. 1993 Aug;265(2 Pt 1):C571–C576. [PubMed]
  • Kirschenlohr HL, Metcalfe JC, Weissberg PL, Grainger DJ. Proliferation of human aortic vascular smooth muscle cells in culture is modulated by active TGF beta. Cardiovasc Res. 1995 Jun;29(6):848–855. [PubMed]
  • Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol. 1989 Jul;109(1):309–315. [PMC free article] [PubMed]
  • Flaumenhaft R, Abe M, Sato Y, Miyazono K, Harpel J, Heldin CH, Rifkin DB. Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells. J Cell Biol. 1993 Feb;120(4):995–1002. [PMC free article] [PubMed]
  • Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):580–584. [PMC free article] [PubMed]
  • Kovacina KS, Steele-Perkins G, Purchio AF, Lioubin M, Miyazono K, Heldin CH, Roth RA. Interactions of recombinant and platelet transforming growth factor-beta 1 precursor with the insulin-like growth factor II/mannose 6-phosphate receptor. Biochem Biophys Res Commun. 1989 Apr 14;160(1):393–403. [PubMed]
  • Wang S, Souza RF, Kong D, Yin J, Smolinski KN, Zou TT, Frank T, Young J, Flanders KC, Sugimura H, et al. Deficient transforming growth factor-beta1 activation and excessive insulin-like growth factor II (IGFII) expression in IGFII receptor-mutant tumors. Cancer Res. 1997 Jul 1;57(13):2543–2546. [PubMed]
  • Purchio AF, Cooper JA, Brunner AM, Lioubin MN, Gentry LE, Kovacina KS, Roth RA, Marquardt H. Identification of mannose 6-phosphate in two asparagine-linked sugar chains of recombinant transforming growth factor-beta 1 precursor. J Biol Chem. 1988 Oct 5;263(28):14211–14215. [PubMed]
  • Brunner AM, Gentry LE, Cooper JA, Purchio AF. Recombinant type 1 transforming growth factor beta precursor produced in Chinese hamster ovary cells is glycosylated and phosphorylated. Mol Cell Biol. 1988 May;8(5):2229–2232. [PMC free article] [PubMed]
  • Miyazono K, Heldin CH. Role for carbohydrate structures in TGF-beta 1 latency. Nature. 1989 Mar 9;338(6211):158–160. [PubMed]
  • Taipale J, Saharinen J, Hedman K, Keski-Oja J. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils. J Histochem Cytochem. 1996 Aug;44(8):875–889. [PubMed]
  • Raghunath M, Unsöld C, Kubitscheck U, Bruckner-Tuderman L, Peters R, Meuli M. The cutaneous microfibrillar apparatus contains latent transforming growth factor-beta binding protein-1 (LTBP-1) and is a repository for latent TGF-beta1. J Invest Dermatol. 1998 Oct;111(4):559–564. [PubMed]
  • Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int. 1997 May;51(5):1376–1382. [PubMed]
  • Sato Y, Okada F, Abe M, Seguchi T, Kuwano M, Sato S, Furuya A, Hanai N, Tamaoki T. The mechanism for the activation of latent TGF-beta during co-culture of endothelial cells and smooth muscle cells: cell-type specific targeting of latent TGF-beta to smooth muscle cells. J Cell Biol. 1993 Dec;123(5):1249–1254. [PMC free article] [PubMed]
  • Yang Y, Dignam JD, Gentry LE. Role of carbohydrate structures in the binding of beta1-latency-associated peptide to ligands. Biochemistry. 1997 Sep 30;36(39):11923–11932. [PubMed]
  • Taipale J, Miyazono K, Heldin CH, Keski-Oja J. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol. 1994 Jan;124(1-2):171–181. [PMC free article] [PubMed]
  • Verderio E, Gaudry C, Gross S, Smith C, Downes S, Griffin M. Regulation of cell surface tissue transglutaminase: effects on matrix storage of latent transforming growth factor-beta binding protein-1. J Histochem Cytochem. 1999 Nov;47(11):1417–1432. [PubMed]
  • Kojima S, Nara K, Rifkin DB. Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol. 1993 Apr;121(2):439–448. [PMC free article] [PubMed]
  • Nunes I, Shapiro RL, Rifkin DB. Characterization of latent TGF-beta activation by murine peritoneal macrophages. J Immunol. 1995 Aug 1;155(3):1450–1459. [PubMed]
  • Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF. Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol. 1995 Oct;131(2):539–549. [PMC free article] [PubMed]
  • Nakajima Y, Miyazono K, Kato M, Takase M, Yamagishi T, Nakamura H. Extracellular fibrillar structure of latent TGF beta binding protein-1: role in TGF beta-dependent endothelial-mesenchymal transformation during endocardial cushion tissue formation in mouse embryonic heart. J Cell Biol. 1997 Jan 13;136(1):193–204. [PMC free article] [PubMed]
  • Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993 Jun 11;260(5114):1655–1658. [PubMed]
  • Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994 Mar 31;368(6470):419–424. [PubMed]
  • Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992 Oct 22;359(6397):693–699. [PMC free article] [PubMed]
  • Shipley JM, Mecham RP, Maus E, Bonadio J, Rosenbloom J, McCarthy RT, Baumann ML, Frankfater C, Segade F, Shapiro SD. Developmental expression of latent transforming growth factor beta binding protein 2 and its requirement early in mouse development. Mol Cell Biol. 2000 Jul;20(13):4879–4887. [PMC free article] [PubMed]
  • Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998 Jun 26;93(7):1159–1170. [PubMed]
  • Hyytiäinen M, Taipale J, Heldin CH, Keski-Oja J. Recombinant latent transforming growth factor beta-binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to proteolytic processing and release. J Biol Chem. 1998 Aug 7;273(32):20669–20676. [PubMed]
  • Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest. 1991 Sep;88(3):904–910. [PMC free article] [PubMed]
  • Kanzaki T, Tamura K, Takahashi K, Saito Y, Akikusa B, Oohashi H, Kasayuki N, Ueda M, Morisaki N. In vivo effect of TGF- beta 1. Enhanced intimal thickening by administration of TGF- beta 1 in rabbit arteries injured with a balloon catheter. Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1951–1957. [PubMed]
  • Smith JD, Bryant SR, Couper LL, Vary CP, Gotwals PJ, Koteliansky VE, Lindner V. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res. 1999 May 28;84(10):1212–1222. [PubMed]
  • Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, et al. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10759–10763. [PMC free article] [PubMed]
  • Schulick AH, Taylor AJ, Zuo W, Qiu CB, Dong G, Woodward RN, Agah R, Roberts AB, Virmani R, Dichek DA. Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6983–6988. [PMC free article] [PubMed]
  • Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J Clin Invest. 1994 Mar;93(3):1172–1178. [PMC free article] [PubMed]
  • Grainger DJ, Kemp PR, Witchell CM, Weissberg PL, Metcalfe JC. Transforming growth factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase. Biochem J. 1994 Apr 1;299(Pt 1):227–235. [PMC free article] [PubMed]
  • Metcalfe JC, Grainger DJ. Transforming growth factor-beta and the protection from cardiovascular injury hypothesis. Biochem Soc Trans. 1995 May;23(2):403–406. [PubMed]
  • Williams JK, Wagner JD, Li Z, Golden DL, Adams MR. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol. 1997 Feb;17(2):403–408. [PubMed]
  • Grainger DJ, Witchell CM, Metcalfe JC. Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med. 1995 Oct;1(10):1067–1073. [PubMed]
  • Reckless J, Metcalfe JC, Grainger DJ. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation. 1997 Mar 18;95(6):1542–1548. [PubMed]
  • McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ. 1991 Aug 24;303(6800):435–437. [PMC free article] [PubMed]
  • Van Laethem JL, Resibois A, Adler M, Peny MO, Ohtani H, Robberecht P. Localization of transforming growth factor-beta 1 precursor and latent TGF-beta 1 binding protein in colorectal adenomas. Dig Dis Sci. 1996 Sep;41(9):1741–1748. [PubMed]
  • Eklöv S, Funa K, Nordgren H, Olofsson A, Kanzaki T, Miyazono K, Nilsson S. Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue. Cancer Res. 1993 Jul 1;53(13):3193–3197. [PubMed]
  • Chaudhry A, Oberg K, Gobl A, Heldin CH, Funa K. Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res. 1994 Sep-Oct;14(5B):2085–2091. [PubMed]
  • Van Laethem JL, Resibois A, Rickaert F, Devière J, Gelin M, Cremer M, Robberecht P. Different expression of transforming growth factor beta 1 in pancreatic ductal adenocarcinoma and cystic neoplasms. Pancreas. 1997 Jul;15(1):41–47. [PubMed]
  • Henriksen R, Gobl A, Wilander E, Oberg K, Miyazono K, Funa K. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest. 1995 Aug;73(2):213–220. [PubMed]
  • Mizoi T, Ohtani H, Miyazono K, Miyazawa M, Matsuno S, Nagura H. Immunoelectron microscopic localization of transforming growth factor beta 1 and latent transforming growth factor beta 1 binding protein in human gastrointestinal carcinomas: qualitative difference between cancer cells and stromal cells. Cancer Res. 1993 Jan 1;53(1):183–190. [PubMed]
  • Karonen T, Jeskanen L, Keski-Oja J. Transforming growth factor beta 1 and its latent form binding protein-1 associate with elastic fibres in human dermis: accumulation in actinic damage and absence in anetoderma. Br J Dermatol. 1997 Jul;137(1):51–58. [PubMed]
  • van Laethem JL, Deviere J, Resibois A, Rickaert F, Vertongen P, Ohtani H, Cremer M, Miyazono K, Robberecht P. Localization of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitis. Gastroenterology. 1995 Jun;108(6):1873–1881. [PubMed]
  • Taketazu F, Kato M, Gobl A, Ichijo H, ten Dijke P, Itoh J, Kyogoku M, Rönnelid J, Miyazono K, Heldin CH, et al. Enhanced expression of transforming growth factor-beta s and transforming growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis. Lab Invest. 1994 May;70(5):620–630. [PubMed]
  • Nakayama M, Okuda S, Tamaki K, Shimizu F, Kawachi H, Ando T, Yanagida T, Fujishima M. Roles of TGF-beta and latent TGF-beta-binding protein in glomerulosclerosis induced by two consecutive injections of monoclonal antibody 1-22-3 in rats. Nephron. 1997;76(1):82–89. [PubMed]
  • Wada T, Hamakawa S, Hori Y, Kaname S, Shimizu S, Kurokawa K, Katoh T. Immunohistochemical localization of latent transforming growth factor-beta binding protein in IgA nephropathy. Kidney Int Suppl. 1997 Dec;63:S182–S184. [PubMed]
  • Tamaki K, Okuda S, Miyazono K, Nakayama M, Fujishima M. Matrix-associated latent TGF-beta with latent TGF-beta binding protein in the progressive process in adriamycin-induced nephropathy. Lab Invest. 1995 Jul;73(1):81–89. [PubMed]
  • Tamaki K, Okuda S, Nakayama M, Yanagida T, Fujishima M. Transforming growth factor-beta 1 in hypertensive renal injury in Dahl salt-sensitive rats. J Am Soc Nephrol. 1996 Dec;7(12):2578–2589. [PubMed]
  • Hori Y, Katoh T, Hirakata M, Joki N, Kaname S, Fukagawa M, Okuda T, Ohashi H, Fujita T, Miyazono K, et al. Anti-latent TGF-beta binding protein-1 antibody or synthetic oligopeptides inhibit extracellular matrix expression induced by stretch in cultured rat mesangial cells. Kidney Int. 1998 Jun;53(6):1616–1625. [PubMed]
  • Yamazaki M, Minota S, Sakurai H, Miyazono K, Yamada A, Kanazawa I, Kawai M. Expression of transforming growth factor-beta 1 and its relation to endomysial fibrosis in progressive muscular dystrophy. Am J Pathol. 1994 Feb;144(2):221–226. [PMC free article] [PubMed]
  • Waltenberger J, Lundin L, Oberg K, Wilander E, Miyazono K, Heldin CH, Funa K. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol. 1993 Jan;142(1):71–78. [PMC free article] [PubMed]
  • Maeda J, Ueki N, Ohkawa T, Iwahashi N, Nakano T, Hada T, Higashino K. Local production and localization of transforming growth factor-beta in tuberculous pleurisy. Clin Exp Immunol. 1993 Apr;92(1):32–38. [PMC free article] [PubMed]
  • Stenman G, Sahlin P, Olofsson A, Geurts van Kessel A, Miyazono K. Assignment of the gene encoding the latent TGF-beta 1-binding protein (LTBP1) to human chromosome 2, region p12-->q22. Cytogenet Cell Genet. 1994;66(2):117–119. [PubMed]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    PubChem Compound links
  • Gene
    Gene links
  • Gene (nucleotide)
    Gene (nucleotide)
    Records in Gene identified from shared sequence links
  • GEO Profiles
    GEO Profiles
    Related GEO records
  • HomoloGene
    HomoloGene links
  • MedGen
    Related information in MedGen
  • Nucleotide
    Published Nucleotide sequences
  • OMIM
    OMIM record citing PubMed
  • Protein
    Published protein sequences
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...